ZURICH: Novartis’ struggling Alcon eye care division will take longer to turn around than expected, the Swiss drugmaker’s chief executive Joe Jimenez warned as he reported a smaller-than-forecast fall in third quarter net income.
Alcon’s sales this quarter would be “flat to down slightly,” Jimenez said, after predicting earlier this year that the division’s new head Michael Ball would have it growing at a low-single-digit percentage rate by the year-end.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
